Drugs Made In America Acquisition Corp. (DMAA) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$10.88

From 52W high−0.09%

Volume10047.00

Market cap$264.13M

P/E (TTM)55.4x

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$10.88

From 52W high

−0.09%

Volume

10047.00

Market cap

$264.13M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−100.7x

P/E (TTM)

55.4x

RSI (14)

62.8

MomentumView details →

1D Return

+0.00%

YTD Return

+4.97%

SummaryUpdated Jun 1, 2026

Drugs Made In America Acquisition Corp. (NASDAQ:DMAAU) is a special purpose acquisition company (SPAC) founded on May 23, 2024, and headquartered in Fort Lauderdale, Florida. The company went public on January 27, 2025, as a blank check company designed to identify and merge with or acquire businesses in the pharmaceutical and healthcare sectors. As a newly formed entity, DMAAU operates as an investment vehicle seeking to complete a business combination with one or more target companies, with a particular focus on businesses involved in domestic pharmaceutical manufacturing and related healthcare services.

Ask drillr about Drugs Made In America Acquisition Corp. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

55.4x

EV/EBITDA

−100.7x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

4.42%

ROA (TTM)

4.15%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−99.85%

FCF YoY

+46.96%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+439.29%

EBITDA YoY

—

MomentumView details →

1D Return

+0.00%

YTD Return

+4.97%

1Y Return

+5.47%

RSI (14)

62.8

vs 50D SMA

+0.39%

vs 200D SMA

+2.31%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

0.02x

Quick Ratio

0.02x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

6.09M

Op. CF (TTM)

−323129.00

Latest newsMore news →

Drugs Made In America Acquisition Corp. entered into an Amended and Restated Definitive Merger Agreement with Power Analytics Global Corp, fixing a closing valuation of US$2.85 billion for the merger.51d ago

Similar companies

Oaktree Acquisition Corp. III Life SciencesOACC Perimeter Acquisition Corp. IPMTRU Blue Water Acquisition Corp IIIBLUWU FACT II Acquisition CorpFACT Newbury Street II Acquisition CorpNTWO Fifth Era Acquisition Corp I UnitsFERAU Find similar companies →

Latest newsMore news →